The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production

In prospect of developing an oral dosage form of Infliximab, for treatment of Crohn's disease and rheumatoid arthritis, freeze-drying (vial vs Lyoguard trays) and spray-drying were investigated as production method for stable powders. Dextran and inulin were used in combination with sucrose as...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-10, Vol.11 (10), p.e0163109-e0163109
Main Authors: Kanojia, Gaurav, Have, Rimko Ten, Bakker, Arjen, Wagner, Koen, Frijlink, Henderik W, Kersten, Gideon F A, Amorij, Jean-Pierre
Format: Article
Language:English
Subjects:
Analysis
Arthritis
Binding
Biological activity
Biological products
Biology and Life Sciences
Chemical modification
Chromatography, Gel
Crohn's disease
Dextran
Dextrans
Dextrans - chemistry
Drug Compounding - methods
Drug Stability
Electrophoresis, Polyacrylamide Gel
Feasibility studies
Formulations
Freeze Drying
Heat treatment
Hydrogen
Immunoglobulin G
Immunoglobulins
Immunotherapy
Infliximab
Infliximab - analysis
Infliximab - chemistry
Inulin
Inulin - chemistry
Maillard Reaction
Maillard reaction products
Medical treatment
Monoclonal antibodies
Pharmaceutical industry
Pharmaceutical sciences
Physical Sciences
Powder
Powders (Particulate matter)
Proteins
Research and Analysis Methods
Rheumatoid arthritis
Rheumatoid factor
Sucrose
Sucrose - chemistry
Sugar
Trays
Tumor necrosis factor
Tumor necrosis factor-TNF
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c725t-ab5f2f677f65a6eab74dd86db5b1014620c373addba846a5e43adace2927f6063
cites cdi_FETCH-LOGICAL-c725t-ab5f2f677f65a6eab74dd86db5b1014620c373addba846a5e43adace2927f6063
container_end_page e0163109
container_issue 10
container_start_page e0163109
container_title PloS one
container_volume 11
creator Kanojia, Gaurav
Have, Rimko Ten
Bakker, Arjen
Wagner, Koen
Frijlink, Henderik W
Kersten, Gideon F A
Amorij, Jean-Pierre
description In prospect of developing an oral dosage form of Infliximab, for treatment of Crohn's disease and rheumatoid arthritis, freeze-drying (vial vs Lyoguard trays) and spray-drying were investigated as production method for stable powders. Dextran and inulin were used in combination with sucrose as stabilizing excipients. The drying processes did not affect Infliximab in these formulations, i.e. both the physical integrity and biological activity (TNF binding) were retained. Accelerated stability studies (1 month at 60°C) showed that the TNF binding ability of Infliximab was conserved in the freeze-dried formulations, whereas the liquid counterpart lost all TNF binding. After thermal treatment, the dried formulations showed some chemical modification of the IgG in the dextran-sucrose formulation, probably due to Maillard reaction products. This study indicates that, with the appropriate formulation, both spray-drying and freeze-drying may be useful for (bulk) powder production of Infliximab.
doi_str_mv 10.1371/journal.pone.0163109
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1826186388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A471821352</galeid><doaj_id>oai_doaj_org_article_a744f781d7084e29aa53d9244b99c94c</doaj_id><sourcerecordid>A471821352</sourcerecordid><originalsourceid>FETCH-LOGICAL-c725t-ab5f2f677f65a6eab74dd86db5b1014620c373addba846a5e43adace2927f6063</originalsourceid><addsrcrecordid>eNqNk11v0zAUhiMEYmPwDxBEQkJw0WLHXwkXSNPYoNKkTXRwa53YTpvJjTs7GSu_HoemU4N2MeXCsf28r33O8UmS1xhNMRH407XrfAN2unaNmSLMCUbFk-QQFySb8AyRp3v_B8mLEK4RYiTn_HlykAmBOBbsMKmulia99E53qq1dk7oqhXTeQmlNOmsqW9_VKyjTS_dbG_857enTW7Ad7Oj52sMmhUanZ96YP2by1W_qZpFWzu_5vkyeVWCDeTWMR8nPs9Ork--T84tvs5Pj84kSGWsnULIqq7gQFWfADZSCap1zXbISI0xjKIoIAlqXkFMOzNA4AWWyIosSxMlR8nbru7YuyCFFQeI84zjnJM8jMdsS2sG1XPsYnt9IB7X8t-D8QoJva2WNBEFpJXKsBcppPAOAEV1klJZFoQqqoteX4bSuXBmtTNN6sCPT8U5TL-XC3UqGGBaERoMPg4F3N50JrVzVQRlroTGu6-8dw80QZegxaKwuQaJPwrv_0IcTMVALiLHWTeXiFVVvKo-piCAmLIvU9AEqftqsahWfXlXH9ZHg40gQmdbctQvoQpCz-Y_Hsxe_xuz7PXZpwLbL4GzXv64wBukWVN6F4E11Xw-MZN85u2zIvnPk0DlR9ma_lveiXauQvzWIEhY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826186388</pqid></control><display><type>article</type><title>The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Kanojia, Gaurav ; Have, Rimko Ten ; Bakker, Arjen ; Wagner, Koen ; Frijlink, Henderik W ; Kersten, Gideon F A ; Amorij, Jean-Pierre</creator><contributor>Khodarahmi, Reza</contributor><creatorcontrib>Kanojia, Gaurav ; Have, Rimko Ten ; Bakker, Arjen ; Wagner, Koen ; Frijlink, Henderik W ; Kersten, Gideon F A ; Amorij, Jean-Pierre ; Khodarahmi, Reza</creatorcontrib><description>In prospect of developing an oral dosage form of Infliximab, for treatment of Crohn's disease and rheumatoid arthritis, freeze-drying (vial vs Lyoguard trays) and spray-drying were investigated as production method for stable powders. Dextran and inulin were used in combination with sucrose as stabilizing excipients. The drying processes did not affect Infliximab in these formulations, i.e. both the physical integrity and biological activity (TNF binding) were retained. Accelerated stability studies (1 month at 60°C) showed that the TNF binding ability of Infliximab was conserved in the freeze-dried formulations, whereas the liquid counterpart lost all TNF binding. After thermal treatment, the dried formulations showed some chemical modification of the IgG in the dextran-sucrose formulation, probably due to Maillard reaction products. This study indicates that, with the appropriate formulation, both spray-drying and freeze-drying may be useful for (bulk) powder production of Infliximab.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0163109</identifier><identifier>PMID: 27706175</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Analysis ; Arthritis ; Binding ; Biological activity ; Biological products ; Biology and Life Sciences ; Chemical modification ; Chromatography, Gel ; Crohn's disease ; Dextran ; Dextrans ; Dextrans - chemistry ; Drug Compounding - methods ; Drug Stability ; Electrophoresis, Polyacrylamide Gel ; Feasibility studies ; Formulations ; Freeze Drying ; Heat treatment ; Hydrogen ; Immunoglobulin G ; Immunoglobulins ; Immunotherapy ; Infliximab ; Infliximab - analysis ; Infliximab - chemistry ; Inulin ; Inulin - chemistry ; Maillard Reaction ; Maillard reaction products ; Medical treatment ; Monoclonal antibodies ; Pharmaceutical industry ; Pharmaceutical sciences ; Physical Sciences ; Powder ; Powders (Particulate matter) ; Proteins ; Research and Analysis Methods ; Rheumatoid arthritis ; Rheumatoid factor ; Sucrose ; Sucrose - chemistry ; Sugar ; Trays ; Tumor necrosis factor ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α</subject><ispartof>PloS one, 2016-10, Vol.11 (10), p.e0163109-e0163109</ispartof><rights>COPYRIGHT 2016 Public Library of Science</rights><rights>2016 Kanojia et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2016 Kanojia et al 2016 Kanojia et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c725t-ab5f2f677f65a6eab74dd86db5b1014620c373addba846a5e43adace2927f6063</citedby><cites>FETCH-LOGICAL-c725t-ab5f2f677f65a6eab74dd86db5b1014620c373addba846a5e43adace2927f6063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1826186388/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1826186388?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27706175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Khodarahmi, Reza</contributor><creatorcontrib>Kanojia, Gaurav</creatorcontrib><creatorcontrib>Have, Rimko Ten</creatorcontrib><creatorcontrib>Bakker, Arjen</creatorcontrib><creatorcontrib>Wagner, Koen</creatorcontrib><creatorcontrib>Frijlink, Henderik W</creatorcontrib><creatorcontrib>Kersten, Gideon F A</creatorcontrib><creatorcontrib>Amorij, Jean-Pierre</creatorcontrib><title>The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>In prospect of developing an oral dosage form of Infliximab, for treatment of Crohn's disease and rheumatoid arthritis, freeze-drying (vial vs Lyoguard trays) and spray-drying were investigated as production method for stable powders. Dextran and inulin were used in combination with sucrose as stabilizing excipients. The drying processes did not affect Infliximab in these formulations, i.e. both the physical integrity and biological activity (TNF binding) were retained. Accelerated stability studies (1 month at 60°C) showed that the TNF binding ability of Infliximab was conserved in the freeze-dried formulations, whereas the liquid counterpart lost all TNF binding. After thermal treatment, the dried formulations showed some chemical modification of the IgG in the dextran-sucrose formulation, probably due to Maillard reaction products. This study indicates that, with the appropriate formulation, both spray-drying and freeze-drying may be useful for (bulk) powder production of Infliximab.</description><subject>Analysis</subject><subject>Arthritis</subject><subject>Binding</subject><subject>Biological activity</subject><subject>Biological products</subject><subject>Biology and Life Sciences</subject><subject>Chemical modification</subject><subject>Chromatography, Gel</subject><subject>Crohn's disease</subject><subject>Dextran</subject><subject>Dextrans</subject><subject>Dextrans - chemistry</subject><subject>Drug Compounding - methods</subject><subject>Drug Stability</subject><subject>Electrophoresis, Polyacrylamide Gel</subject><subject>Feasibility studies</subject><subject>Formulations</subject><subject>Freeze Drying</subject><subject>Heat treatment</subject><subject>Hydrogen</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulins</subject><subject>Immunotherapy</subject><subject>Infliximab</subject><subject>Infliximab - analysis</subject><subject>Infliximab - chemistry</subject><subject>Inulin</subject><subject>Inulin - chemistry</subject><subject>Maillard Reaction</subject><subject>Maillard reaction products</subject><subject>Medical treatment</subject><subject>Monoclonal antibodies</subject><subject>Pharmaceutical industry</subject><subject>Pharmaceutical sciences</subject><subject>Physical Sciences</subject><subject>Powder</subject><subject>Powders (Particulate matter)</subject><subject>Proteins</subject><subject>Research and Analysis Methods</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatoid factor</subject><subject>Sucrose</subject><subject>Sucrose - chemistry</subject><subject>Sugar</subject><subject>Trays</subject><subject>Tumor necrosis factor</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAUhiMEYmPwDxBEQkJw0WLHXwkXSNPYoNKkTXRwa53YTpvJjTs7GSu_HoemU4N2MeXCsf28r33O8UmS1xhNMRH407XrfAN2unaNmSLMCUbFk-QQFySb8AyRp3v_B8mLEK4RYiTn_HlykAmBOBbsMKmulia99E53qq1dk7oqhXTeQmlNOmsqW9_VKyjTS_dbG_857enTW7Ad7Oj52sMmhUanZ96YP2by1W_qZpFWzu_5vkyeVWCDeTWMR8nPs9Ork--T84tvs5Pj84kSGWsnULIqq7gQFWfADZSCap1zXbISI0xjKIoIAlqXkFMOzNA4AWWyIosSxMlR8nbru7YuyCFFQeI84zjnJM8jMdsS2sG1XPsYnt9IB7X8t-D8QoJva2WNBEFpJXKsBcppPAOAEV1klJZFoQqqoteX4bSuXBmtTNN6sCPT8U5TL-XC3UqGGBaERoMPg4F3N50JrVzVQRlroTGu6-8dw80QZegxaKwuQaJPwrv_0IcTMVALiLHWTeXiFVVvKo-piCAmLIvU9AEqftqsahWfXlXH9ZHg40gQmdbctQvoQpCz-Y_Hsxe_xuz7PXZpwLbL4GzXv64wBukWVN6F4E11Xw-MZN85u2zIvnPk0DlR9ma_lveiXauQvzWIEhY</recordid><startdate>20161005</startdate><enddate>20161005</enddate><creator>Kanojia, Gaurav</creator><creator>Have, Rimko Ten</creator><creator>Bakker, Arjen</creator><creator>Wagner, Koen</creator><creator>Frijlink, Henderik W</creator><creator>Kersten, Gideon F A</creator><creator>Amorij, Jean-Pierre</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20161005</creationdate><title>The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production</title><author>Kanojia, Gaurav ; Have, Rimko Ten ; Bakker, Arjen ; Wagner, Koen ; Frijlink, Henderik W ; Kersten, Gideon F A ; Amorij, Jean-Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c725t-ab5f2f677f65a6eab74dd86db5b1014620c373addba846a5e43adace2927f6063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>Arthritis</topic><topic>Binding</topic><topic>Biological activity</topic><topic>Biological products</topic><topic>Biology and Life Sciences</topic><topic>Chemical modification</topic><topic>Chromatography, Gel</topic><topic>Crohn's disease</topic><topic>Dextran</topic><topic>Dextrans</topic><topic>Dextrans - chemistry</topic><topic>Drug Compounding - methods</topic><topic>Drug Stability</topic><topic>Electrophoresis, Polyacrylamide Gel</topic><topic>Feasibility studies</topic><topic>Formulations</topic><topic>Freeze Drying</topic><topic>Heat treatment</topic><topic>Hydrogen</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulins</topic><topic>Immunotherapy</topic><topic>Infliximab</topic><topic>Infliximab - analysis</topic><topic>Infliximab - chemistry</topic><topic>Inulin</topic><topic>Inulin - chemistry</topic><topic>Maillard Reaction</topic><topic>Maillard reaction products</topic><topic>Medical treatment</topic><topic>Monoclonal antibodies</topic><topic>Pharmaceutical industry</topic><topic>Pharmaceutical sciences</topic><topic>Physical Sciences</topic><topic>Powder</topic><topic>Powders (Particulate matter)</topic><topic>Proteins</topic><topic>Research and Analysis Methods</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatoid factor</topic><topic>Sucrose</topic><topic>Sucrose - chemistry</topic><topic>Sugar</topic><topic>Trays</topic><topic>Tumor necrosis factor</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanojia, Gaurav</creatorcontrib><creatorcontrib>Have, Rimko Ten</creatorcontrib><creatorcontrib>Bakker, Arjen</creatorcontrib><creatorcontrib>Wagner, Koen</creatorcontrib><creatorcontrib>Frijlink, Henderik W</creatorcontrib><creatorcontrib>Kersten, Gideon F A</creatorcontrib><creatorcontrib>Amorij, Jean-Pierre</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Opposing Viewpoints in Context (Gale)</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database (ProQuest)</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection (ProQuest Medical &amp; Health Databases)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (ProQuest Medical &amp; Health Databases)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanojia, Gaurav</au><au>Have, Rimko Ten</au><au>Bakker, Arjen</au><au>Wagner, Koen</au><au>Frijlink, Henderik W</au><au>Kersten, Gideon F A</au><au>Amorij, Jean-Pierre</au><au>Khodarahmi, Reza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2016-10-05</date><risdate>2016</risdate><volume>11</volume><issue>10</issue><spage>e0163109</spage><epage>e0163109</epage><pages>e0163109-e0163109</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>In prospect of developing an oral dosage form of Infliximab, for treatment of Crohn's disease and rheumatoid arthritis, freeze-drying (vial vs Lyoguard trays) and spray-drying were investigated as production method for stable powders. Dextran and inulin were used in combination with sucrose as stabilizing excipients. The drying processes did not affect Infliximab in these formulations, i.e. both the physical integrity and biological activity (TNF binding) were retained. Accelerated stability studies (1 month at 60°C) showed that the TNF binding ability of Infliximab was conserved in the freeze-dried formulations, whereas the liquid counterpart lost all TNF binding. After thermal treatment, the dried formulations showed some chemical modification of the IgG in the dextran-sucrose formulation, probably due to Maillard reaction products. This study indicates that, with the appropriate formulation, both spray-drying and freeze-drying may be useful for (bulk) powder production of Infliximab.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>27706175</pmid><doi>10.1371/journal.pone.0163109</doi><tpages>e0163109</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2016-10, Vol.11 (10), p.e0163109-e0163109
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1826186388
source Publicly Available Content (ProQuest); PubMed Central
subjects Analysis
Arthritis
Binding
Biological activity
Biological products
Biology and Life Sciences
Chemical modification
Chromatography, Gel
Crohn's disease
Dextran
Dextrans
Dextrans - chemistry
Drug Compounding - methods
Drug Stability
Electrophoresis, Polyacrylamide Gel
Feasibility studies
Formulations
Freeze Drying
Heat treatment
Hydrogen
Immunoglobulin G
Immunoglobulins
Immunotherapy
Infliximab
Infliximab - analysis
Infliximab - chemistry
Inulin
Inulin - chemistry
Maillard Reaction
Maillard reaction products
Medical treatment
Monoclonal antibodies
Pharmaceutical industry
Pharmaceutical sciences
Physical Sciences
Powder
Powders (Particulate matter)
Proteins
Research and Analysis Methods
Rheumatoid arthritis
Rheumatoid factor
Sucrose
Sucrose - chemistry
Sugar
Trays
Tumor necrosis factor
Tumor necrosis factor-TNF
Tumor necrosis factor-α
title The Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for Production
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T09%3A29%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Production%20of%20a%20Stable%20Infliximab%20Powder:%20The%20Evaluation%20of%20Spray%20and%20Freeze-Drying%20for%20Production&rft.jtitle=PloS%20one&rft.au=Kanojia,%20Gaurav&rft.date=2016-10-05&rft.volume=11&rft.issue=10&rft.spage=e0163109&rft.epage=e0163109&rft.pages=e0163109-e0163109&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0163109&rft_dat=%3Cgale_plos_%3EA471821352%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c725t-ab5f2f677f65a6eab74dd86db5b1014620c373addba846a5e43adace2927f6063%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1826186388&rft_id=info:pmid/27706175&rft_galeid=A471821352&rfr_iscdi=true